These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 11043500)

  • 1. Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases.
    Brevetti G; De Caterina M; Martone VD; Corrado S; Silvestro A; Spadaro G; Scopacasa F
    Int J Clin Lab Res; 2000; 30(2):75-81. PubMed ID: 11043500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
    Mittag M; Beckheinrich P; Haustein UF
    Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
    Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
    Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
    Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
    Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
    Lau CS; McLaren M; Mackay I; Belch JJ
    Ann Rheum Dis; 1993 Jun; 52(6):443-8. PubMed ID: 8323396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.
    Kahaleh MB; Osborn I; LeRoy EC
    Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.
    Denton CP; Howell K; Stratton RJ; Black CM
    Clin Exp Rheumatol; 2000; 18(4):499-502. PubMed ID: 10949727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin.
    Verhaar MC; Beutler JJ; Gaillard CA; Koomans HA; Fijnheer R; Rabelink TJ
    J Hypertens; 1998 Jan; 16(1):45-50. PubMed ID: 9533416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood viscosity and local response to cold in primary Raynaud's phenomenon.
    Jahnsen T; Nielsen SL; Skovborg F
    Lancet; 1977 Nov; 2(8046):1001-2. PubMed ID: 72898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes.
    Mohamed-Ali V; Armstrong L; Clarke D; Bolton CH; Pinkney JH
    J Intern Med; 2001 Nov; 250(5):415-21. PubMed ID: 11887976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
    Priollet P; Vayssairat M; Housset E
    Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pathogenic role for endothelin in Raynaud's phenomenon?
    Bottomley W; Goodfield M
    Acta Derm Venereol; 1994 Nov; 74(6):433-4. PubMed ID: 7701873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating adhesion molecules in patients with vibration-induced white finger.
    Kurozawa Y; Nasu Y
    Angiology; 2000 Dec; 51(12):1003-6. PubMed ID: 11132991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Raynaud's disease and Raynaud's phenomenon in connective tissue diseases].
    Sicińska J; Rudnicka L
    Pol Arch Med Wewn; 2002 Oct; 108(4):1011-22. PubMed ID: 12642947
    [No Abstract]   [Full Text] [Related]  

  • 17. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke.
    Blann A; Kumar P; Krupinski J; McCollum C; Beevers DG; Lip GY
    Blood Coagul Fibrinolysis; 1999 Jul; 10(5):277-84. PubMed ID: 10456619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.
    Zamora MR; O'Brien RF; Rutherford RB; Weil JV
    Lancet; 1990 Nov; 336(8724):1144-7. PubMed ID: 1978025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble circulating cell adhesion molecules in haemolytic uraemic syndrome.
    Inward CD; Pall AA; Adu D; Milford DV; Taylor CM
    Pediatr Nephrol; 1995 Oct; 9(5):574-8. PubMed ID: 8580013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.